ACADIA Pharmaceuticals Inc. (ACAD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 17.07 |
| Open | 16.98 |
| Bid | 16.81 x 200 |
| Ask | 16.84 x 200 |
| Day's Range | 16.62 - 17.30 |
| 52 Week Range | 16.60 - 33.99 |
| Volume | |
| Avg. Volume | 1,806,161 |
| Market Cap | 2.771B |
| Beta (5Y Monthly) | 0.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GuruFocus.com
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders, has reported an insider sell transaction.
- GuruFocus.com
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares
Stephen Davis, the CEO of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), has sold 17,714 shares of the company on March 27, 2024, according to a recent SEC filing.
- Investor's Business Daily
Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study
Acadia stock crashed Tuesday after an outsized placebo effect torpedoed the company's efforts to expand Nuplazid to schizophrenia patients.
© 2024 Yahoo. All rights reserved.